Abstract
Botulinum toxin is one of the most toxic natural substances; it acts by blocking the neuromuscular transmission by inhibiting Acetylcholine (Ach) releasing from the motor nerve into the neuromuscular junction. Although the toxin inhibits ACh release, other transmitters can also be inhibited. Botulinum toxin, specifically toxin type A (BONT-A) has been used since the 1970s to treat many different disorders, such as general spasticity resulting from stroke, multiple sclerosis or cerebral palsy, strabismus, hyperhidrosis or excessive sweating, pain, and it is effective in combating migraine and tension headaches. Since prostate gland is under the influence of autonomic innervation and associated neurotransmitters, the effects of BONT-A on the prostate have gained attention in the urological community and it has been studied in different species, including rats, dogs and humans. The aim of this paper is to review the mechanism of action of botulinum toxin and to discuss in particular the results of BONT-A treatment for benign prostatic hyperplasia (BPH), providing perspectives on potential therapy according to actual knowledge.
Keywords: botulinum toxin, animal prostate, human prostate, prostate, lower urinary tract symptoms, benign prostatic hyperplasia, LUTS, BPH
Current Drug Delivery
Title: Botulinum Toxin a in Prostate Disease: A Venom from Bench to Bed-Side
Volume: 9 Issue: 1
Author(s): Luigi Mearini and Antonella Giannantoni
Affiliation:
Keywords: botulinum toxin, animal prostate, human prostate, prostate, lower urinary tract symptoms, benign prostatic hyperplasia, LUTS, BPH
Abstract: Botulinum toxin is one of the most toxic natural substances; it acts by blocking the neuromuscular transmission by inhibiting Acetylcholine (Ach) releasing from the motor nerve into the neuromuscular junction. Although the toxin inhibits ACh release, other transmitters can also be inhibited. Botulinum toxin, specifically toxin type A (BONT-A) has been used since the 1970s to treat many different disorders, such as general spasticity resulting from stroke, multiple sclerosis or cerebral palsy, strabismus, hyperhidrosis or excessive sweating, pain, and it is effective in combating migraine and tension headaches. Since prostate gland is under the influence of autonomic innervation and associated neurotransmitters, the effects of BONT-A on the prostate have gained attention in the urological community and it has been studied in different species, including rats, dogs and humans. The aim of this paper is to review the mechanism of action of botulinum toxin and to discuss in particular the results of BONT-A treatment for benign prostatic hyperplasia (BPH), providing perspectives on potential therapy according to actual knowledge.
Export Options
About this article
Cite this article as:
Mearini Luigi and Giannantoni Antonella, Botulinum Toxin a in Prostate Disease: A Venom from Bench to Bed-Side, Current Drug Delivery 2012; 9 (1) . https://dx.doi.org/10.2174/156720112798375970
DOI https://dx.doi.org/10.2174/156720112798375970 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Imaging in the Age of Molecular Medicine: Monitoring of Anti-Angiogenic Treatments
Current Pharmaceutical Biotechnology PPARγ in Angiogenesis and Vascular Development
Current Angiogenesis (Discontinued) Involvement of CD24 in Multiple Cancer Related Pathways Makes It an Interesting New Target for Cancer Therapy
Current Cancer Drug Targets Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitors in Cancer
Current Drug Targets Evolution of Ipsilateral Head and Neck Radiotherapy
Current Cancer Therapy Reviews Recent Advances in PET Imaging for Skeletal Surgery Applications
Recent Patents on Medical Imaging Meet the Editorial Board:
Anti-Cancer Agents in Medicinal Chemistry Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) Chiral BrOnsted Acid-Catalyzed Friedel-Crafts Reaction of Indoles
Current Organic Chemistry Recent Advances in Synthesis and Identification of Cyclic Peptides for Bioapplications
Current Topics in Medicinal Chemistry Gut Homing Molecule Regulation of the Pathogenesis and Treatment of Inflammatory Bowel Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Cytochromes P450 and Skin Cancer: Role of Local Endocrine Pathways
Anti-Cancer Agents in Medicinal Chemistry Current and Emerging Therapies in Neuroendocrine Tumors: Impact of Genetic Targets on Clinical Outcomes
Clinical Cancer Drugs Selected Approaches for Rational Drug Design and High Throughput Screening to Identify Anti-Cancer Molecules
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Polycomb Targeting in Human Cancer
Recent Patents on Regenerative Medicine Targeting Ion Channels for New Strategies in Cancer Diagnosis and Therapy
Current Clinical Pharmacology Chemokines as Pharmacological Targets
Mini-Reviews in Medicinal Chemistry Blocking the PI3K/PKB Pathway in Tumor Cells
Current Medicinal Chemistry - Anti-Cancer Agents Development of Genomics-Based Gene Expression Signature Biomarkers in Oncology and Toxicology to Facilitate Drug Discovery and Translational Medicine
Current Bioinformatics Effects of Salinomycin on Cancer Stem Cell in Human Lung Adenocarcinoma A549 Cells
Medicinal Chemistry